

# CONTENTS

---

SUMMARY .....	1
SUMMARY IN JAPANESE .....	2
INTRODUCTION .....	5
OBJECTIVES .....	7
METHODOLOGY .....	9
RESPONSE.....	13
RESULTS .....	15
COMPANY STRATEGY FOR ICH .....	15
Implementation of ICH guidelines.....	17
Problems experienced with implementation of ICH guidelines .....	18
IMPACT OF ICH EFFICACY GUIDELINES .....	20
Patient Numbers.....	20
Drug development and study time .....	21
Cost of clinical development .....	23
Quality of the efficacy assessment.....	24
Conduct of clinical trials and submission strategies .....	25
Benefits for companies .....	27
POTENTIAL IMPACT OF THE E5 GUIDELINE .....	29
Suggested modifications and improvements to the E5 guideline .....	30
Impact of the E5 guideline .....	31
THE FUTURE OF ICH .....	32
Positive and negative outcomes .....	32
The global dossier .....	33
Continuation of ICH .....	34
DISCUSSION .....	35
ACKNOWLEDGEMENT .....	39
REFERENCES .....	41

---

APPENDICES .....	43
Appendix I - the questionnaire.....	45
Appendix II - companies invited to participate.....	59
Appendix III - steps in the ICH process.....	61